Recombinant Human IL-6 Protein (His Tag)

Catalog Number: PDEH100712

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description			
Species	Human		
Source	Ecoli-derived Human IL-6 protein Val30-Met212, with an N-terminal His		
Calculated MW	20.8 kDa		
Observed MW	25-28 kDa		
Accession	P05231		
Bio-activity	Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED		
	$_{50}$ for this effect is 0.27 to 0.81 ng/mL.		
Properties			
Purity	> 90% as determined by reducing SDS-PAGE.		
Endotoxin	< 10 EU/mg of the protein as determined by the LAL method		
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80		
	°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of		
	reconstituted samples are stable at $< -20^{\circ}$ C for 3 months.		
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.		
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with 5% Trehalose and 5%		
	Mannitol.		
Reconstitution	It is recommended that sterile water be added to the vial to prepare a stock solution of		
	0.5 mg/mL. Concentration is measured by UV-Vis.		

Data

kDa 80 60	MK	R
40	-	
30		_
20		-
12	U	

> 90 % as determined by reducing SDS-PAGE.

Background

Elabscience®

Interleukin-6 (IL-6) is a pleiotropic, alpha-helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progressio n. IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (I L-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alpha association with gp130 and gp130 dimerization. Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage. In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha. Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes. Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor. IL-6, along with TNF-alpha and IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis. IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise.